Approving clinical investigations

AI Summary

This guidance document, issued by the UK Medicines and Healthcare products Regulatory Agency (MHRA), outlines the administrative procedures and expected timelines for clinical investigation applications within Great Britain and Northern Ireland. The MHRA’s primary objective is to streamline the application review process while maintaining a high standard of patient safety. The regulatory framework emphasizes that any potential risks to participants must be minimized and clearly outweighed by the projected clinical benefits of the investigation. While the provided text does not reference a specific company, inspection dates, or individual violations, it serves as a foundational regulatory directive for all medical device manufacturers intending to conduct clinical trials in the United Kingdom. Applicants are required to align their submissions with these established protocols and should consult supplementary guidance on medical device clinical investigations to ensure full compliance. The document underscores the necessity of a rigorous justification for every proposed study, ensuring that human subject protection remains the priority during the review of investigative medical technologies. Consequently, stakeholders must adhere to the specified timetables to facilitate efficient regulatory oversight and timely market access for innovative medical solutions.